Introduction {#section1-0009922819861281}
============

While the teratogenic activities of cannabis have been investigated since the 1960s,^[@bibr1-0009922819861281],[@bibr2-0009922819861281]^ substantially higher levels of Δ9-tetrahydrocannabinol of currently used cannabis^[@bibr3-0009922819861281]^ suggests that the neonatal epidemiology of former years requires reexamination.^[@bibr4-0009922819861281],[@bibr5-0009922819861281]^

Urgency for epidemiological reassessment achieves particular currency in view of recent US data indicating that 24% of pregnant Californian teenagers test positive for cannabinoids,^[@bibr6-0009922819861281]^ that 69% of pregnant Coloradan mothers have cannabis recommended to them by cannabis dispensaries,^[@bibr7-0009922819861281]^ and that 161 000 pregnant women across the United States admitted to cannabis use during their pregnancy.^[@bibr8-0009922819861281]^

In such a context, experience from flagship states such as Colorado, which has been a pioneer in US cannabis use and also supports a detailed and public database of congenital defects, is invaluable to ascertain current trends and likely future directions. Cannabis was permitted for medicinal use from November 2000 and was decreed legal in November 2011 with full effect from 2014.

Colorado also has one other considerable advantage that greatly simplifies the statistical analysis of its data, as during the period 2000 to 2014, nationally representative datasets indicate that the use of other drugs was static or falling. In this sense, therefore, the Coloradan context is ideal from a statistical and public health perspective to ascertain current teratological trends while statistically isolating the effect of rising cannabinoid exposure to facilitate the study of prenatal cannabis exposure (PCE).

This study explores the presence of any overall trends in the pattern of Coloradan congenital anomalies data and investigates the extent to which ecologically documented drug use trends explained some of this variance.

Methods {#section2-0009922819861281}
=======

Data {#section3-0009922819861281}
----

Data on birth defects in Colorado were taken from the Colorado Responds to Children with Special Needs (CRCSN) online database as single data points in January 2019.^[@bibr9-0009922819861281]^ Total 2013 defect data were taken from the April 2018 CRCSN dataset. Data on drug use were taken from the National Survey of Drug Use and Health (NSDUH) conducted annually by the Substance Abuse and Mental Health Administration (SAMHSA).^[@bibr8-0009922819861281]^ Data on cannabinoid concentration were taken from the National Drug Enforcement Agency seizures^[@bibr10-0009922819861281],[@bibr11-0009922819861281]^ and multiplied by annual cannabis use to derive state-wide cannabinoid exposure.

Relationship to Cannabis {#section4-0009922819861281}
------------------------

Defects were classified as cannabis-related if strong published evidence had previously identified a relationship to cannabis exposure. Papers from Centers for Disease Control and Prevention (CDC) and National Birth Defects Prevention Network (NBDPN) have established that anencephaly,^[@bibr12-0009922819861281],[@bibr13-0009922819861281]^ diaphragmatic hernia, esophageal atresia with or without tracheoesophageal fistula, and gastroschisis are cannabis-related.^[@bibr12-0009922819861281]^ A joint statement by the American Academy of Pediatrics and the American Heart Association linked Ebstein's anomaly and ventricular septal defect (VSD) with cannabis use.^[@bibr14-0009922819861281]^ A large 2007 epidemiological study from Hawaii also linked encephalocele, hypoplastic left heart, syndactyly, reduction deformity of the upper limbs, hydrocephaly, cleft lip and cleft palate both separately and together, anotia/microtia, tetralogy of Fallot, pyloric stenosis, microcephaly, pulmonary valve atresia and/or stenosis, large bowel or rectal atresias or stenosis, obstructive genitourinary defect, polydactyly, atrial septal defect (ASD), and trisomy 21 with PCE.^[@bibr15-0009922819861281]^ Although this study is an outlier in terms of the literature, this list of defects was accepted as being cannabis-related in view of its high predictive value and pointed real-world applicability particularly in the United States (see Results and Discussion sections).

Statistics {#section5-0009922819861281}
----------

Data were processed in "R" v3.5.2 and "R Studio" v1.1.463 from the Central "R" Archive Network. Model reduction was conducted by the classical method with progressive removal of the least significant term. Models were compared by analysis of variance (ANOVA). Model parameters were compared with the "purrr" and "broom" packages. Regression line slope change was assessed with the "segmented" package. Differing quantitative scales were adjusted using the "scales" package. The "nlme" package was used for mixed-effects regression. Principal components analysis was conducted using the "psych" package. *P* \< .05 was considered significant.

Ethics {#section6-0009922819861281}
------

The study was approved by the Human Research Ethics Committees of South City Medical Centre and the University of Western Australia.

Results {#section7-0009922819861281}
=======

The January 2019 CRCSN dataset consists of annual numbers and rates on 49 defects for each of the years 2000 through 2014 and comprises 746 data points together with 180 data points relating to 13 summary indices by major organ system. These defects are graphed by time in [Figures 1](#fig1-0009922819861281){ref-type="fig"} and [2](#fig2-0009922819861281){ref-type="fig"}.

![Colorado congenital defects A-E by time, regression lines fitted.](10.1177_0009922819861281-fig1){#fig1-0009922819861281}

![Colorado congenital defects H-V by time, regression lines fitted.](10.1177_0009922819861281-fig2){#fig2-0009922819861281}

[Table 1](#table1-0009922819861281){ref-type="table"} lists the slope and confidence intervals of these time-dependent changes. Seven defects are noted to be significantly rising and 2 significantly falling. [Table 2](#table2-0009922819861281){ref-type="table"} repeats this exercise for the major defect summary groups. Nine of 11 slopes are noted to be rising. [Supplementary Figures 1 and 2](https://journals.sagepub.com/doi/suppl/10.1177/0009922819861281) (available online) present loess curves for these data.

###### 

Time-Dependent Trends of CRCSN Defects.

![](10.1177_0009922819861281-table1)

  Defect                                                  Term   β-Estimate   Standard Error   *t*       *P*     Lower CI   Upper CI
  ------------------------------------------------------- ------ ------------ ---------------- --------- ------- ---------- ----------
  Atrial septal defect secundum                           Year   6.4518       0.7943           8.1229    .0000   4.7359     8.1677
  Ventricular septal defect                               Year   1.1825       0.1623           7.2866    .0000   0.8319     1.5331
  Patent ductus arteriosus                                Year   0.9925       0.2382           4.1660    .0011   0.4778     1.5072
  Chromosomal anomalies                                   Year   0.6543       0.1545           4.2357    .0010   0.3206     0.9880
  Anomalies pulmonary artery                              Year   0.4621       0.3210           1.4396    .1736   −0.2314    1.1556
  Microcephalus                                           Year   0.3046       0.0812           3.7519    .0024   0.1292     0.4801
  Trisomy 21                                              Year   0.1850       0.0673           2.7480    .0166   0.0396     0.3304
  Renal agenesis                                          Year   0.0961       0.0394           2.4378    .0299   0.0109     0.1812
  Total anencephalus and spina bifida                     Year   0.0843       0.0467           1.8052    .0942   −0.0166    0.1852
  Hirschsprung's                                          Year   0.0754       0.0457           1.6485    .1232   −0.0234    0.1741
  Spina bifida without anencephalus                       Year   0.0693       0.0405           1.7094    .1111   −0.0183    0.1568
  Anomalies abdominal wall                                Year   0.0507       0.0528           0.9610    .3541   −0.0633    0.1647
  Choanal atresia                                         Year   0.0489       0.0405           1.2086    .2483   −0.0385    0.1364
  Microphthalmos                                          Year   0.0296       0.0305           0.9723    .3486   −0.0362    0.0955
  Endocardial cushion defects                             Year   0.0221       0.0434           0.5106    .6182   −0.0716    0.1158
  Anencephalus                                            Year   0.0154       0.0224           0.6847    .5056   −0.0331    0.0638
  Trisomy 18                                              Year   0.0150       0.0267           0.5619    .5838   −0.0427    0.0727
  Anophthalmos                                            Year   0.0139       0.0218           0.6402    .5332   −0.0331    0.0609
  Encephalocele                                           Year   0.0129       0.0110           1.1654    .2648   −0.0110    0.0367
  Transposition great vessels                             Year   0.0107       0.0540           0.1983    .8458   −0.1060    0.1274
  Congenital biliary atresia                              Year   0.0096       0.0273           0.3538    .7291   −0.0492    0.0685
  Exstrophy urinary bladder                               Year   0.0072       0.0166           0.4304    .6770   −0.0305    0.0448
  Common ventricle                                        Year   0.0064       0.0284           0.2266    .8242   −0.0548    0.0677
  Coarctation aorta                                       Year   0.0032       0.0768           0.0418    .9673   −0.1628    0.1692
  Congenital scoliosis                                    Year   0.0029       0.0234           0.1222    .9046   −0.0477    0.0534
  Polydactyly syndactyly                                  Year   −0.0014      0.1724           −0.0083   .9935   −0.3738    0.3710
  Leg reduction                                           Year   −0.0018      0.0324           −0.0551   .9569   −0.0717    0.0682
  Congenital buphthalmos                                  Year   −0.0032      0.0157           −0.2043   .8413   −0.0372    0.0308
  Common truncus                                          Year   −0.0032      0.0267           −0.1205   .9059   −0.0608    0.0544
  Orofacial anomalies                                     Year   −0.0046      0.0921           −0.0504   .9606   −0.2036    0.1943
  Hypoplastic left heart                                  Year   −0.0096      0.0367           −0.2631   .7966   −0.0888    0.0695
  Cleft Lip with/without cleft palate                     Year   −0.0114      0.0828           −0.1381   .8923   −0.1903    0.1674
  Limb reduction                                          Year   −0.0125      0.0330           −0.3785   .7112   −0.0838    0.0588
  Trisomy 13                                              Year   −0.0125      0.0235           −0.5311   .6043   −0.0633    0.0383
  Tracheoesophageal fistula esophageal atresia stenosis   Year   −0.0146      0.0475           −0.3086   .7625   −0.1172    0.0879
  Anomalies diaphragm                                     Year   −0.0146      0.0543           −0.2697   .7917   −0.1320    0.1027
  Total anomalous pulmonary venous connection             Year   −0.0204      0.0262           −0.7768   .4512   −0.0770    0.0363
  Cleft palate without cleft lip                          Year   −0.0214      0.0916           −0.2340   .8186   −0.2193    0.1764
  Atresia stenosis bladder neck                           Year   −0.0304      0.0391           −0.7759   .4517   −0.1149    0.0542
  Congenital hydrocephalus without spina bifida           Year   −0.0318      0.0584           −0.5443   .5954   −0.1579    0.0944
  Tetralogy Fallot                                        Year   −0.0389      0.0524           −0.7425   .4710   −0.1522    0.0743
  Arm reduction                                           Year   −0.0414      0.0381           −1.0881   .2963   −0.1237    0.0408
  Cong stenosis aortic valve                              Year   −0.0568      0.0337           −1.6866   .1155   −0.1295    0.0160
  Hip dysplasia                                           Year   −0.0639      0.1674           −0.3819   .7087   −0.4256    0.2977
  Congenital cataract                                     Year   −0.0689      0.0346           −1.9903   .0680   −0.1437    0.0059
  Atresia stenosis large intestine                        Year   −0.0936      0.0641           −1.4594   .1682   −0.2321    0.0449
  Infantile cerebral palsy                                Year   −0.1325      0.0730           −1.8158   .0925   −0.2901    0.0251
  Pyloric stenosis                                        Year   −0.2529      0.1057           −2.3912   .0326   −0.4813    −0.0244
  Pulmonary valve stenosis atresia                        Year   −0.3271      0.1009           −3.2417   .0064   −0.5452    −0.1091

Abbreviations: CRCSN, Colorado Responds to Children with Special Needs; CI, confidence interval.

###### 

Time-Dependent Trends of CRCSN Major Defect Classes.

![](10.1177_0009922819861281-table2)

  Defect                            Term   β-Estimate   Standard Error   *t*       *P*       Lower CI   Upper CI
  --------------------------------- ------ ------------ ---------------- --------- --------- ---------- ----------
  Major Defects Number 2013         Year   228.4791     17.7906          12.8427   .000000   189.7167   267.2415
  Major Defects Number 2014         Year   92.9179      11.5577          8.0395    .000002   67.9489    117.8868
  Major Defects Rate 2014           Year   15.6757      2.2823           6.8684    .000011   10.7451    20.6063
  Major Genitourinary Defects       Year   6.1111       0.6297           9.7052    .000000   4.7508     7.4714
  Major Cardiovascular Defects      Year   6.0657       0.8369           7.2476    .000006   4.2576     7.8738
  Major Musculoskeletal Anomalies   Year   3.6582       0.5886           6.2149    .000031   2.3866     4.9298
  Major Musculoskeletal Defects     Year   3.6329       0.5912           6.1449    .000035   2.3556     4.9101
  Respiratory Anomalies             Year   1.9304       0.2758           6.9991    .000009   1.3345     2.5262
  Chromosomal Anomalies             Year   0.6543       0.1545           4.2360    .000973   0.3210     0.9880
  Major Gastrointestinal Defects    Year   0.2061       0.3224           0.6393    .533760   −0.4903    0.9025
  Major Eyes Defects                Year   0.0289       0.0807           0.3585    .725688   −0.1454    0.2032

Abbreviations: CRCSN, Colorado Responds to Children with Special Needs; CI, confidence interval.

Since the data are rather difficult to mentally digest en masse, [Figures 3](#fig3-0009922819861281){ref-type="fig"} to [8](#fig8-0009922819861281){ref-type="fig"} present data grouped by organ system. [Figure 9](#fig9-0009922819861281){ref-type="fig"} illustrates the summary data by organ system.

![Central nervous system (CNS) defects by time.](10.1177_0009922819861281-fig3){#fig3-0009922819861281}

![Neural tube defects by time.](10.1177_0009922819861281-fig4){#fig4-0009922819861281}

![Cardiovascular defects by time.](10.1177_0009922819861281-fig5){#fig5-0009922819861281}

![Chromosomal defects by time.](10.1177_0009922819861281-fig6){#fig6-0009922819861281}

![Face defects by time.](10.1177_0009922819861281-fig7){#fig7-0009922819861281}

![Limb defects by time.](10.1177_0009922819861281-fig8){#fig8-0009922819861281}

![Major defects by time.](10.1177_0009922819861281-fig9){#fig9-0009922819861281}

[Figure 10](#fig10-0009922819861281){ref-type="fig"} shows the numbers of defects as a total number and as a percentage of live born babies. The total figure in the April 2018 CRCSN dataset is noted to be substantially higher than that in the January 2019 CRCSN dataset. [Figure 11](#fig11-0009922819861281){ref-type="fig"} shows the relative rise from baseline of the various categories with the origin of each dataset forming the baseline comparator for that group.

![Total defects by time.](10.1177_0009922819861281-fig10){#fig10-0009922819861281}

![Relative rises in selected defects compared with baseline by time.](10.1177_0009922819861281-fig11){#fig11-0009922819861281}

[Supplementary Table 1](https://journals.sagepub.com/doi/suppl/10.1177/0009922819861281) (available online) shows the summaries of regression models for these major defects and defect classes. [Table 3](#table3-0009922819861281){ref-type="table"} lists the number of cases in each group by year, sums the total, compares it with the calculated total based on 15 times (2000:2014) the lowest rate in either 2000 or 2001, calculates the absolute and relative case excess, and compares it with the rise in births from 2000 to 2014 of 3.3069%. These relative case excesses are then graphed in order in [Figure 12](#fig12-0009922819861281){ref-type="fig"}.

###### 

Case Excess.

![](10.1177_0009922819861281-table3)

  Population                  Specific Defects   Major Systems   Total                                                                                                         
  --------------------------- ------------------ --------------- --------- --------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- --------
  2000                        65 429             30              18        299       244      272      78       159      898      184      1101     860      157      4026     4830
  2001                        67 006             33              10        382       239      261      74       168      999      199      1176     800      183      3514     4942
  2002                        68 420             38              18        518       268      254      92       179      1196     203      1240     856      193      3795     5406
  2003                        69 325             38              21        548       263      285      104      174      1194     207      1297     814      200      3797     5311
  2004                        68 491             46              25        568       263      316      88       213      1295     221      1322     814      223      3909     5482
  2005                        68 929             47              21        571       277      303      95       197      1280     230      1355     929      205      4080     5978
  2006                        70 732             63              15        578       247      314      99       212      1303     223      1430     927      204      4168     6325
  2007                        69 580             55              23        553       266      296      97       212      1218     254      1434     927      235      4111     6213
  2008                        70 024             71              22        770       312      337      81       253      1436     303      1543     1004     195      4592     7010
  2009                        68 603             67              30        922       352      317      106      246      1478     293      1550     1025     238      4637     6826
  2010                        66 339             64              17        887       331      328      96       250      1434     296      1444     1112     257      4666     7171
  2011                        65 026             65              26        866       313      314      88       253      1483     348      1515     1008     227      4728     7174
  2012                        65 173             46              19        912       324      342      95       231      1498     370      1744     966      220      4619     6939
  2013                        64 996             56              18        880       324      380      100      264      1585     345      1668     1164     213      5117     8165
  2014                        65 817             51              24        785       277      359      97       224      1346     282      1581     1058     225      4704     
                                                                                                                                                                               
  Total                       1 013 890          770             307       10039     4300     4678     1390     3235     19643    3958     21400    14264    3175     64463    87772
  Calculated total            981 435            450             150       4485      3660     3915     1110     2385     13470    2760     16515    12000    2355     52710    67620
  Case excess                 32 455             320             157       5554      640      763      280      850      6173     1198     4885     2264     820      11753    20152
  \% Excess                   3.3069%            71.11%          104.67%   123.84%   17.49%   19.49%   25.23%   35.64%   45.83%   43.41%   29.58%   18.87%   34.82%   22.30%   29.80%
  Excess relative to births   1.00               21.50           31.65     37.45     5.29     5.89     7.63     10.78    13.86    13.13    8.94     5.71     10.53    6.74     9.01

Abbreviations: CNS, central nervous system; CVS, cardiovascular system.

![Rise in selected defects relative to rise in births by time.](10.1177_0009922819861281-fig12){#fig12-0009922819861281}

En passant one notes that the rate of rise of the 2 common cardiac defects ASD (secundum type) and patent ductus arteriosus (PDA) appears to rise sigmoidally across this time period of the cannabis legalization process ([Figure 13](#fig13-0009922819861281){ref-type="fig"}). One notes that the quartic model accounts for the time-dependent variance significantly better than the linear model for both ASD (ANOVA *F* = 6.6319, degrees of freedom \[df\] = 3, *P* = .0096) and PDA (ANOVA *F* = 5.413, df = 3, *P* = .018).

![Atrial septal defect, ventricular septal defect, and patent ductus arteriosus---Loess curves by time.](10.1177_0009922819861281-fig13){#fig13-0009922819861281}

Since both the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists concur that drug use in the peripartum period is harmful to the fetus,^[@bibr16-0009922819861281],[@bibr17-0009922819861281]^ it is reasonable to consider the potential role of drug use by the parents in a possible epidemiological association with this overall increasing defect profile.

Drug use in Colorado is presented from the SAMHSA NSDUH data as least squares regression lines in [Figure 14](#fig14-0009922819861281){ref-type="fig"}, and the slopes of these lines are summarized in [Table 4](#table4-0009922819861281){ref-type="table"}. Only the slopes of the cannabis curves are seen to be rising; the slopes of the tobacco, cigarette, cocaine, and pain reliever curves are falling significantly.

![Drug use in Colorado from National Survey of Drug Use and Health (NSDUH) dataset by time with regression lines fitted.](10.1177_0009922819861281-fig14){#fig14-0009922819861281}

###### 

Regression Slope Trend Estimates for Drug Use---NSDUH.

![](10.1177_0009922819861281-table4)

  Drugs                Term   β-Estimate   Standard Error   *t*       *P*     Lower CI   Upper CI
  -------------------- ------ ------------ ---------------- --------- ------- ---------- ----------
  Cannabis---Annual    Year   0.6509       0.1107           5.8808    .0001   0.4097     0.8921
  Cannabis---Monthly   Year   0.5822       0.0960           6.0671    .0001   0.3731     0.7913
  Alcohol Monthly      Year   0.1498       0.0825           1.8159    .0925   −0.0284    0.3281
  Binge Alcohol        Year   0.0703       0.0896           0.7842    .4481   −0.1250    0.2656
  Cocaine Annual       Year   −0.0592      0.0260           −2.2795   .0417   −0.1158    −0.0026
  Pain Relievers       Year   −0.0849      0.0358           −2.3698   .0419   −0.1660    −0.0039
  Tobacco Monthly      Year   −0.2859      0.0933           −3.0651   .0098   −0.4892    −0.0827
  Cigarettes Monthly   Year   −0.3743      0.0817           −4.5838   .0005   −0.5507    −0.1979

Abbreviations: NSDUH, National Survey of Drug Use and Health; CI, confidence interval.

[Figure 15](#fig15-0009922819861281){ref-type="fig"} presents these drug use data with loess curves. Formal testing for change of regression slope for monthly cannabis use showed a significant change in 2007 from .0293 to .11917 (Davies test, *k* = 3, *P* = .0002).

![Drug use in Colorado from National Survey of Drug Use and Health (NSDUH) dataset by time with loess curves fitted.](10.1177_0009922819861281-fig15){#fig15-0009922819861281}

Monthly cannabinoid exposure was calculated by multiplying the concentration of Federal cannabis seizures by within-state monthly cannabis use. These data are presented as regression lines and loess curves in [Figures 16](#fig16-0009922819861281){ref-type="fig"} and [17](#fig17-0009922819861281){ref-type="fig"}.

![Cannabinoid exposure in Colorado from National Survey of Drug Use and Health (NSDUH) dataset by time with regression lines fitted.](10.1177_0009922819861281-fig16){#fig16-0009922819861281}

![Cannabinoid exposure in Colorado from National Survey of Drug Use and Health (NSDUH) dataset by time with loess curves fitted.](10.1177_0009922819861281-fig17){#fig17-0009922819861281}

Because many of the 49 defects had different quantitative rates, they were scaled to mean of 0 and standard deviation of 1 using the "scales" package. The time-dependent plots shown in [Figure 18](#fig18-0009922819861281){ref-type="fig"} were obtained.

![Scaled drug use in Colorado from National Survey of Drug Use and Health dataset by time with loess curves fitted.](10.1177_0009922819861281-fig18){#fig18-0009922819861281}

A similar exercise was conducted, illustrated in [Figure 19](#fig19-0009922819861281){ref-type="fig"}, which charts the scaled defect rate as a linear temporal function of the various drug exposures. Increasing levels of binge alcohol, cocaine, cannabis, and pain relievers are all noted to be linked to higher rates of congenital defects. These relationships are demonstrated in [Table 5](#table5-0009922819861281){ref-type="table"}. One notes that the quartic model for cannabis has a higher *F* value and lower model *P* value than that for opioid pain relievers (7.83 vs 4.422 and 3.5 × 10^−7^ vs 3.4 × 10^−5^).

![Scaled drug use in Colorado from National Survey of Drug Use and Health dataset by time with regression lines fitted.](10.1177_0009922819861281-fig19){#fig19-0009922819861281}

###### 

Regression Slopes for All Scaled Defects by Drug Classes.

![](10.1177_0009922819861281-table5)

  Parameter                  Model                                                             
  -------------------------- ---------- --------- -------- --------- ---------- ------- ------ ----------
  **Linear models**                                                                            
  *Cannabis*                                                                                   
  Cannabis_Monthly           −9.4175    4.3409    −2.169   0.0304    0.005634   2.932   2680   .05395
  Year:Cannabis_Monthly      0.0047     0.0021    2.173    0.0301                              
  *Opioids*                                                                                    
  Year                       0.3486     0.1756    1.985    0.0477    0.009133   2.644   3532   .04856
  Pain_Relevers              112.5612   62.2827   1.807    0.0713                              
  Year:Pain_Relevers         −0.0559    0.0310    −1.804   0.0718                              
  **Quartic models**                                                                           
  *Tobacco*                                                                                    
  (Year)\^3: Tobacco         5.1567     1.7701    2.913    0.0037    0.04503    5.02    8674   4.55E-06
  (Year)\^3                  −145.182   51.2001   −2.836   0.0047                              
  *Alcohol*                                                                                    
  NS                                                                                           
  *Cannabis*                                                                                   
  (Year)\^2                  −13.6307   3.5007    −3.894   0.00011   0.0477     7.833   5677   3.51E-07
  (Year)\^3                  4.8938     1.5169    3.226    0.00132                             
  (Year)\^4                  −9.6683    1.6810    −5.751   1.3E-08                             
  Cannabis_Monthly           0.2002     0.0710    2.822    0.00492                             
  *Opioids*                                                                                    
  Year                       −610.237   228.352   −2.672   0.0078    0.04869    4.422   8527   3.39E-05
  (Year)\^4                  −309.336   103.395   −2.992   0.0029                              
  (Year)\^2: Pain_Relevers   83.360     35.953    2.319    0.0208                              
  (Year)\^4: Pain_Relevers   69.235     22.935    3.019    0.0027                              
  *Cocaine*                                                                                    
  (Year)\^2                  32.2730    14.3249   2.253    0.0246    0.04574    5.087   8674   3.67E-06
  (Year)\^2: Cocaine         −13.2694   5.0409    −2.632   0.0087                              

Abbreviation: df, degrees of freedom.

[Table 6](#table6-0009922819861281){ref-type="table"} compares the defect rates against multiple drug exposure in additive models and increasingly complex interactive mixed-effects models with defect as the random variable. Terms including cannabis exposure persisted in final models.

###### 

Regression Slopes for All Scaled Defects Against Various Drugs---Mixed-Effects Models.

![](10.1177_0009922819861281-table6)

  Parameter                                                          Parameter   Model                                                    
  ------------------------------------------------------------------ ----------- ---------- ----- --------- ------- ---------- ---------- -----------
  **Additive model**                                                                                                                      
  *Rate\~Year+Cannabis_Monthly+Opioids+Tobacco+Cocaine+BingeAlc*                                                                          
  Opioids                                                            0.3479      0.1560     278   2.2311    .0265   848.7998   867.4013   −419.3999
  Year                                                               0.0448      0.0214     278   2.0954    .0370                         
  **Increasing levels of interactive models**                                                                                             
  *Rate\~Year\*Cannabis_Monthly+Opioids+Tobacco+Cocaine+BingeAlc*                                                                         
  Opioids                                                            0.4003      0.1756     278   2.2796    .0234   863.8158   882.4173   −426.9079
  Year:Cannabis_Monthly                                              0.0000      0.0000     278   2.0248    .0438                         
  *Rate\~Year\*Cannabis_Monthly\*Opioids+Tobacco+Cocaine+BingeAlc*                                                                        
  Year                                                               6.3170      1.6760     273   3.7689    .0002   861.0326   898.0704   −420.5163
  Opioids                                                            2489.7840   680.8430   273   3.6569    .0003                         
  Year: Opioids                                                      −1.2360     0.3390     273   −3.6495   .0003                         
  Cannabis_Monthly: Opioids                                          −392.6320   114.0330   273   −3.4431   .0007                         
  Year: Cannabis_Monthly: Opioids                                    0.1950      0.0570     273   3.4470    .0007                         
  Cannabis_Monthly                                                   2101.5210   617.6850   273   3.4023    .0008                         
  Year: Cannabis_Monthly                                             −1.0440     0.3060     273   −3.4071   .0008                         
  *Rate\~Year\*Cannabis_Monthly\*Tobacco+Opioids+Cocaine+BingeAlc*                                                                        
  Year: Cannabis_Monthly                                             −0.0030     0.0009     275   −4.0238   .0001   875.2932   904.9767   −429.6466
  Cannabis_Monthly: Tobacco                                          0.2550      0.0637     275   4.0089    .0001                         
  Year                                                               5.5130      1.4606     275   3.7741    .0002                         
  Tobacco                                                            396.3240    105.2453   275   3.7657    .0002                         
  Year: Tobacco                                                      −0.1990     0.0527     275   −3.7677   .0002                         
  *Rate\~Year+Cannabis_Monthly\*Opioids\*Tobacco+Cocaine+BingeAlc*                                                                        
  Opioids: Tobacco                                                   −0.4067     0.1071     272   −3.7971   .0002   866.9679   907.6728   −422.4839
  Cannabis_Monthly: Opioids: Tobacco                                 0.1857      0.0530     272   3.5015    .0005                         
  Cannabis_Monthly: Opioids                                          −4.4878     1.2866     272   −3.4882   .0006                         
  Cannabis_Monthly                                                   18.7962     5.6135     272   3.3484    .0009                         
  Cannabis_Monthly: Tobacco                                          −0.7761     0.2343     272   −3.3130   .0010                         
  Cocaine                                                            −1.5894     0.5995     272   −2.6510   .0085                         
  Opioids                                                            6.2896      3.0387     272   2.0698    .0394                         

Abbreviations: df, degrees of freedom; AIC, Akaike information criterion; BIC, Bayesian information criterion; LogLik, log likelihood.

As described in Methods, defects were assigned to be either cannabis-related or not based on reports in the published literature. However, as the Hawaiian report of pyloric stenosis being cannabis-linked^[@bibr15-0009922819861281]^ has not been confirmed elsewhere, this condition was removed from the cannabis-associated group. Moreover, 2 reports from CDC/NBDPN indicate that PCE is linked with anencephaly.^[@bibr12-0009922819861281],[@bibr13-0009922819861281]^ Several drugs linked with anencephaly are similarly linked with spina bifida, which is accepted to be a prototypical neural tube closure defect so that it seems likely that cannabis may also be linked with spina bifida with or without anencephaly. Graphs showing the effect of these 2 adjustments are included as [Supplementary Figures 3 to 6](https://journals.sagepub.com/doi/suppl/10.1177/0009922819861281) (available online).

[Figure 20](#fig20-0009922819861281){ref-type="fig"} shows the time relationship of the 49 scaled defects by the above-described relationship to cannabis. These data are shown on single plots with both loess curves and linear regression lines in [Figure 21](#fig21-0009922819861281){ref-type="fig"}.

![Scaled defects rate as a function of drug use exposure with regression lines fitted in facetted plot by relationship to cannabis use, after omission of pyloric stenosis and inclusion of spina bifida.](10.1177_0009922819861281-fig20){#fig20-0009922819861281}

![Scaled defects rate as a function of drug use exposure with (A) loess curves and (B) regression lines fitted.](10.1177_0009922819861281-fig21){#fig21-0009922819861281}

A model quartic-in-time was superior to a linear-only model (ANOVA *F* = 4.6099, df = 5, *P* = .0004).

[Table 7](#table7-0009922819861281){ref-type="table"} shows that the results of both linear and quartic models are significant with cannabis terms remaining in final models both as a factor and in interaction with time and time-squared.

###### 

Comparisons of Cannabinoid Models Linear and Quartic in Time for All Scaled Defects.

![](10.1177_0009922819861281-table7)

  Parameter                                                 Model                                                           
  --------------------------------------------------------- ---------- --------- -------- -------- --------- ------- ------ ----------
  **Linear models**                                                                                                         
  *Defect_Rate \~ Year \* Cannabis_Related*                                                                                 
  Year: Cannabis_Related                                    0.0402     0.0108    3.712    0.0002   0.01523   4.763   3727   .002697
  Cannabis_Related                                          −98.8011   33.3927   −2.959   0.0032                            
  **Quartic-in-time models**                                                                                                
  *Defect_Rate \~ I(poly(Year, n=4)) \* Cannabis_Related*                                                                   
  (Year)\^4                                                 −4.7042    1.4591    −3.224   0.0013   0.03908   4.711   8722   1.20E-05
  Year: Cannabis_Related                                    5.7531     1.9252    2.988    0.0029                            
  (Year)\^2: Cannabis_Related                               −4.8258    1.9287    −2.502   0.0126                            

Abbreviation: df, degrees of freedom.

[Figure 22](#fig22-0009922819861281){ref-type="fig"} shows the time relationship of exposure to various cannabinoids with regression lines, and loess curves are shown in [Supplementary Figure 7](https://journals.sagepub.com/doi/suppl/10.1177/0009922819861281) (available online).

![Scaled defects rate as a function of cannabinoid exposure with loess curves fitted. Facetted plot by cannabinoid.](10.1177_0009922819861281-fig22){#fig22-0009922819861281}

[Figure 23](#fig23-0009922819861281){ref-type="fig"} shows the defects charted against cannabinoid exposure. These relationships are formalized in [Table 8](#table8-0009922819861281){ref-type="table"}.

![Scaled defects rate as a function of cannabinoid exposure with regression lines fitted. Facetted plot by cannabinoid.](10.1177_0009922819861281-fig23){#fig23-0009922819861281}

###### 

Rises in Defects by Cannabinoid Exposure---Models Linear and Quartic in Time.

![](10.1177_0009922819861281-table8)

  Parameter            Model                                                            
  -------------------- ---------- --------- -------- --------- --------- ------- ------ ----------
  **Linear models**                                                                     
  *d8_THC*                                                                              
  Year                 −0.2870    0.1131    −2.537   .0117     0.0169    3.496   2289   .03162
  Year:d8_THCMON       0.0005     0.0002    2.209    .0280                              
  **Quartic models**                                                                    
  *d9_THC*                                                                              
  Year: d9_THC         0.8892     0.3821    2.327    .0203     0.0431    4.84    8674   8.15E-06
  (Year)\^4            −20.9952   9.1100    −2.305   .0215                              
  Year                 −99.5298   49.4149   −2.014   .0444                              
  *CBD*                                                                                 
  (Year)\^3            55.9750    22.1400   2.528    .0117     0.0489    5.378   8674   1.42E-06
  (Year)\^3: CBD       −14.8342   5.9146    −2.508   .0124                              
  *CBN*                                                                                 
  (Year)\^4            −6.6144    1.2950    −5.108   4.3E-07   0.0477    7.832   5577   3.52E-07
  (Year)\^2            −8.8041    2.0599    −4.274   2.2E-05                            
  (Year)\^3            4.8154     1.5064    3.197    .0015                              
  CBN                  0.1645     0.0583    2.821    .0049                              
  *CBG*                                                                                 
  NS                                                                                    
  *THCV*                                                                                
  (Year)\^4            −8.0989    1.4039    −5.769   1.2E-08   0.04671   7.683   5677   4.88E-07
  (Year)\^2            −8.4791    2.0250    −4.187   3.2E-05                            
  THCV                 0.9907     0.3681    2.691    .0073                              
  (Year)\^3            3.7194     1.4095    2.639    .0085                              

Abbreviation: df, degrees of freedom.

[Figure 24](#fig24-0009922819861281){ref-type="fig"} illustrates the complex relationship between monthly cannabis use, falling cannabidiol concentration, and the population exposure to cannabidiol.

![(A) Monthly cannabis use by year. (B) Cannabidiol concentration by year. (C) Cannabidiol exposure by year as the product of (A) and (B).](10.1177_0009922819861281-fig24){#fig24-0009922819861281}

[Figure 25](#fig25-0009922819861281){ref-type="fig"} is a point and box plot graph of the movement of cannabis-related versus nonrelated defects for each year to address the complex relationship of cannabidiol exposure.

![Relationship of scaled defects by year to described relationship to cannabis consumption from the published literature (see Discussion).](10.1177_0009922819861281-fig25){#fig25-0009922819861281}

[Figure 26A](#fig26-0009922819861281){ref-type="fig"} shows these 2 rates side by side from 2000 to 2014. The difference between the 2 groups is plotted in [Figure 26B](#fig26-0009922819861281){ref-type="fig"}, and their adjusted ratio (adjusted by adding unity \[1\] to numerator and denominator) appears in [Figure 26C](#fig26-0009922819861281){ref-type="fig"}. [Figure 26D](#fig26-0009922819861281){ref-type="fig"} shows the ratio of the absolute values of the cannabis-related and non--cannabis-related values, which correlates broadly with cannabidiol exposure ([Figure 24C](#fig24-0009922819861281){ref-type="fig"}, *R* = 0.4857, *P* = .0783). These measures clearly peaked in 2009-2010 when cannabidiol exposure also peaked.

![(A) Box plot of relationship of scaled defects to time by described relationship to cannabis use. (B) Difference between cannabis-related and non--cannabis-related rates of scaled scores. (C) Ratio of cannabis-related and non--cannabis-related scaled scores after adjustment by adding unity (1) to both scores. (D) The ratio of the absolute value of the cannabis-related defects to that of the absolute value of cannabis-unrelated defects.](10.1177_0009922819861281-fig26){#fig26-0009922819861281}

[Figure 9](#fig9-0009922819861281){ref-type="fig"} and [Table 2](#table2-0009922819861281){ref-type="table"} showed that defects in 5 major organ systems are rising: central nervous system, cardiovascular, genitourinary, musculoskeletal, and respiratory systems. These 5 may then be combined by principal component analysis. A scree plot ([Supplementary Figure 8](https://journals.sagepub.com/doi/suppl/10.1177/0009922819861281), available online) shows that 1 principal component---PC1---was sufficient to combine these data and accounted for 90% of the variance. Together with total rates from the CRCSN dataset, this produces 3 summary statistics, the totals for 2013, 2014, and PC1.

[Figure 27](#fig27-0009922819861281){ref-type="fig"} charts these parameters against each other along with the monthly cannabis exposure. A close visual relationship is immediately apparent. These correlations are presented formally in [Table 9](#table9-0009922819861281){ref-type="table"}.

![Line plots showing relationship between scaled (A) major defect rates 2013 and last month cannabis use; (B) major defect rates 2014 and last month cannabis use; (C) principal component 1 and last month cannabis use; (D) major defects 2014 and principal component 1 for 2014.](10.1177_0009922819861281-fig27){#fig27-0009922819861281}

###### 

Correlation Coefficients---Major Summary Indices With Cannabis Use (see [Figure 27](#fig27-0009922819861281){ref-type="fig"}).

![](10.1177_0009922819861281-table9)

  Group 1               Group 2            *t*      df   *P*       *R*      Lower CI   Upper CI
  --------------------- ------------------ -------- ---- --------- -------- ---------- ----------
  Major Defects 2014    Cannabis_Monthly   4.2597   12   .0011     0.7758   0.4169     0.9255
  Major Defects 2013    Cannabis_Monthly   5.1534   11   .0003     0.8409   0.5402     0.9512
  PC1                   Cannabis_Monthly   4.2722   12   .0011     0.7767   0.4187     0.9258
  Majors Defects 2014   PC1                11.035   13   5.7E-08   0.9505   0.8542     0.9838

Abbreviations: df, degrees of freedom; CI, confidence interval.

[Table 10](#table10-0009922819861281){ref-type="table"} summarizes the regression of all scaled defects against various drug combinations.

###### 

Linear Regression of Major Summary Indices by NSDUH Drug Exposure.

![](10.1177_0009922819861281-table10)

  Parameter                                                                                 Model                                                          
  ----------------------------------------------------------------------------------------- ----------- --------- --------- ------- -------- ------- ----- ----------
  **Linear models**                                                                                                                                        
  *Majors2014\~Year+Tobacco\*Cannabis_Monthly+Opioids+Binge_Alcohol+Cocaine*                                                                               
  Cannabis_Monthly                                                                          1.2139      0.1678    7.234     .0002   0.8656   22.48   3,7   .0005718
  Tobacco: Cannabis_Monthly                                                                 0.4423      0.1116    3.964     .0054                          
  Opioids                                                                                   0.3683      0.1373    2.683     .0314                          
  *Majors2014\~Year\*Δ9-THC+CBDM+Tobacco+Opioids*                                                                                                          
  Δ9-THC                                                                                    253.3969    94.7077   2.676     .0281   0.7856   19.33   2,8   .0095
  Year: Δ9-THC                                                                              −0.1257     0.0471    −2.668    .0284                          
  *PC1\~Year+Tobacco\*Cannabis_Monthly+Opioids+Binge_Alcohol+Cocaine*                                                                                      
  Cannabis_Monthly                                                                          1.2404      0.1962    6.322     .0004   0.8221   16.4    3,7   .001508
  Tobacco: Cannabis_Monthly                                                                 0.4829      0.1305    3.701     .0076                          
  Opioids                                                                                   0.3957      0.1605    2.465     .0431                          
  *Major_CNS\~Year+Tobacco\*Cannabis_Monthly+Opioids+Binge_Alcohol+Cocaine*                                                                                
  Cannabis_Monthly                                                                          1.1631      0.2332    4.988     .0016   0.6956   8.619   3,7   .00949
  Opioids                                                                                   0.6071      0.1908    3.182     .0154                          
  Tobacco: Cannabis_Monthly                                                                 0.4133      0.1551    2.665     .0322                          
  *Major_CVS\~Year+Tobacco\*Cannabis_Monthly+Opioids+Binge_Alcohol+Cocaine*                                                                                
  Cannabis_Monthly                                                                          1.1303      0.2331    4.85      .0019   0.6951   8.599   3,7   .009549
  Tobacco: Cannabis_Monthly                                                                 0.4770      0.1550    3.077     .0179                          
  Opioids                                                                                   0.4469      0.1907    2.344     .0516                          
  **Quartic-in-time models**                                                                                                                               
  *PC1\~I(poly(Year, n=4))\*Δ9-THC+CBDM+Tobacco+Opioids*                                                                                                   
  Δ9-THC                                                                                    0.6793      0.1625    4.181     .0024   0.6223   17.48   1,9   .0095
  *Majors2014\~(poly(Year, n=4))\*Cannabis_Monthly+Tobacco+Opioids+Binge_Alcohol+Cocaine*                                                                  
  (Year)\^4: Cannabis_Monthly                                                               −20.4192    0.9427    −21.66    .0294   0.9982   609.9   9,1   .03141
  Year: Cannabis_Monthly                                                                    302.1905    14.3060   21.12     .0301                          
  Cannabis_Monthly                                                                          −58.0400    2.8018    −20.71    .0307                          
  (Year)\^3: Cannabis_Monthly                                                               99.9858     4.8684    20.54     .0310                          
  (Year)\^2: Cannabis_Monthly                                                               −209.6725   10.3174   −20.32    .0313                          
  Year                                                                                      340.6153    16.8783   20.18     .0315                          
  (Year)\^2                                                                                 −270.0904   13.4573   −20.07    .0317                          
  (Year)\^3                                                                                 119.3061    6.4290    18.56     .0343                          
  (Year)\^4                                                                                 −40.3087    2.4539    −16.43    .0387                          
  *PC1\~I(poly(Year, n=4))\*Cannabis_Monthly+Tobacco+Opioids+Binge_Alcohol+Cocaine*                                                                        
  Year: Cannabis_Monthly                                                                    −5.7912     1.1506    −5.033    .0024   0.8062   11.4    4,6   .005744
  (Year)\^2: Cannabis_Monthly                                                               5.0229      1.0371    4.843     .0029                          
  (Year)\^3: Cannabis_Monthly                                                               2.9675      0.8060    3.682     .0103                          
  (Year)\^4: Cannabis_Monthly                                                               −1.6296     0.6479    −2.515    .0456                          
  *Major_CNS\~I(poly(Year, n=4))\*Cannabis_Monthly+Tobacco+Opioids+Binge_Alcohol+Cocaine*                                                                  
  Year: Cannabis_Monthly                                                                    −5.6711     1.5086    −3.759    .0094   0.5964   4.694   4,6   .04649
  (Year)\^2: Cannabis_Monthly                                                               4.2187      1.3598    3.102     .0211                          
  (Year)\^3: Cannabis_Monthly                                                               2.6681      1.0568    2.525     .0450                          
  *Major_CVS\~I(poly(Year, n=4))\*Cannabis_Monthly+Tobacco+Opioids+Binge_Alcohol+Cocaine*                                                                  
  Cannabis_Monthly                                                                          −54.5060    3.3030    −16.5     .0385   0.997    373     9,1   .04016
  Year: Cannabis_Monthly                                                                    274.4250    16.8670   16.27     .0391                          
  (Year)\^2: Cannabis_Monthly                                                               −192.5180   12.1640   −15.827   .0402                          
  (Year)\^4: Cannabis_Monthly                                                               −17.3420    1.1110    −15.604   .0407                          
  Year                                                                                      309.6860    19.8990   15.562    .0409                          
  (Year)\^3: Cannabis_Monthly                                                               84.3810     5.7400    14.701    .0432                          
  (Year)\^2                                                                                 −228.2030   15.8660   −14.383   .0442                          
  (Year)\^3                                                                                 103.9890    7.5800    13.719    .0463                          
  (Year)\^4                                                                                 −28.4810    2.8930    −9.844    .0644                          

Abbreviations: NSDUH, National Survey of Drug Use and Health; df, degrees of freedom.

[Table 11](#table11-0009922819861281){ref-type="table"} is a regression summary for all scaled defects against various cannabinoids.

###### 

Linear Regression of Major Summary Indices Against Selected Cannabinoids.

![](10.1177_0009922819861281-table11)

  Parameter                                                                 Model                                                           
  ------------------------------------------------------------------------- ---------- -------- --------- ------- -------- --------- ------ ---------
  **Quartic-in-time models**                                                                                                                
  **Additive models**                                                                                                                       
  *Majors2014\~poly(Year, n=4)+Δ9-THC+CBD+CBN+THCV*                                                                                         
  Δ9-THC                                                                    0.8746     0.1535   5.699     .0001   0.7077   32.48     1,12   9.9E-05
  *PC1\~poly(Year, n=4)+Δ9-THC+CBD+CBN+THCV*                                                                                                
  Year                                                                      2.5605     0.5875   4.358     .0024   0.9582   60.67     5,8    3.8E-06
  (Year)\^4                                                                 −0.8531    0.2711   −3.147    .0137                             
  (Year)\^2                                                                 −1.0638    0.4303   −2.472    .0386                             
  CBN                                                                       0.4179     0.1789   2.336     .0477                             
  *Major_CVS\~poly(Year, n=4)+Δ9-THC+CBD+CBN+THCV*                                                                                          
  (Year)\^4                                                                 −1.5260    0.3572   −4.273    .0027   0.9149   28.97     5,8    6.4E-05
  (Year)\^2                                                                 −1.9670    0.5670   −3.469    .0085                             
  Year                                                                      2.3018     0.7741   2.974     .0178                             
  CBN                                                                       0.5051     0.2357   2.143     .0645                             
  *Majors2013\~poly(Year, n=4)+Δ9-THC+CBD+CBN+THCV*                                                                                         
  CBD                                                                       −1.3975    0.3085   −4.530    .0062   0.9718   60.04     7,5    .0002
  THCV                                                                      1.1978     0.2796   4.284     .0078                             
  (Year)\^4                                                                 1.9973     0.4900   4.076     .0096                             
  (Year)\^3                                                                 −2.4039    0.6190   −3.884    .0116                             
  (Year)\^2                                                                 −3.5165    1.0913   −3.222    .0234                             
  CBN                                                                       0.8580     0.2758   3.111     .0265                             
  Year                                                                      −8.0678    2.6757   −3.015    .0296                             
  **Interactive models**                                                                                                                    
  *PC1\~poly(Year, n=4)\*Δ9-THC+CBD+CBN+THCV*                                                                                               
  Year: Δ9-THC                                                              −2.1082    0.3168   −6.655    .0006   75.94    75.94     7,6    2.0E-05
  CBD                                                                       −0.3900    0.0713   −5.469    .0016                             
  CBN                                                                       0.5980     0.1536   3.894     .0080                             
  THCV                                                                      0.4206     0.1444   2.914     .0268                             
  *Majors2013\~poly(Year, n=4)\*LMCann+Tob+Opioids+Binge_Alcohol+Cocaine*                                                                   
  (Year)\^3                                                                 4.5310     0.9640   4.700     .0053   0.8206   11.29     4,5    .0102
  Year                                                                      3.0367     0.9432   3.219     .0235                             
  (Year)\^2                                                                 −2.9994    1.1589   −2.588    .0490                             
  *Majors2013\~poly(Year, n=4)\*Δ9-THC+CBD+CBN+THCV*                                                                                        
  Δ9-THC                                                                    3.7695     0.0983   38.354    .0166   0.9999   14750.0   11,1   .0064
  CBD                                                                       −1.2900    0.0356   −36.203   .0176                             
  (Year)\^4: Δ9-THC                                                         9.4066     0.2628   35.801    .0178                             
  Year: Δ9-THC                                                              −31.1351   0.9101   −34.211   .0186                             
  (Year)\^4                                                                 23.1233    0.7273   31.791    .0200                             
  (Year)\^2                                                                 40.8303    1.3204   30.923    .0206                             
  (Year)\^3: Δ9-THC                                                         −23.2475   0.8131   −28.59    .0223                             
  CBN                                                                       1.0334     0.0472   21.908    .0290                             
  Year                                                                      −4.7978    0.3662   −13.103   .0485                             

Abbreviation: df, degrees of freedom.

[Table 12](#table12-0009922819861281){ref-type="table"} presents final regression models of various key summary parameters against the indicated combinations of drugs and cannabinoids in linear and/or time-quartic models.

###### 

Linear Regression of Major Defect Indices Against Drugs and Cannabinoids Together.

![](10.1177_0009922819861281-table12)

  Parameter                                                    Model                                                        
  ------------------------------------------------------------ ---------- --------- -------- ------- -------- ------- ----- ----------
  **Linear models**                                                                                                         
  *Majors2014\~Year\*Δ9-THC+CBDM+Tobacco+Opioids*                                                                           
  Δ9-THC                                                       253.3969   94.7077   2.676    .0281   0.7856   19.33   2,8   .0008648
  Year:Δ9-THC                                                  −0.1257    0.0471    −2.668   .0284                          
  **Quartic-in-time models**                                                                                                
  *Majors2014\~poly(Year, n=4)\*Δ9-THC+CBDM+Tobacco+Opioids*                                                                
  (Year)\^3: Δ9-THC                                            3.8734     1.1020    3.515    .0126   0.7258   7.619   4,6   .01561
  (Year)\^2: Δ9-THC                                            −5.4212    1.5780    −3.435   .0139                          
  Year: Δ9-THC                                                 4.0698     1.3505    3.013    .0236                          
  (Year)\^4: Δ9-THC                                            −1.7240    0.8807    −1.958   .0980                          
  *PC1\~poly(Year, n=4)\*Δ9-THC+CBDM+Tobacco+Opioids*                                                                       
  Δ9-THC                                                       0.6793     0.1625    4.181    .0024   0.6223   17.48   1,9   .002374
  *Major_CNS\~poly(Year, n=4)\*Δ9-THC+CBDM+Tobacco+Opioids*                                                                 
  (Year)\^2: Δ9-THC                                            −6.4699    1.7370    −3.725   .0098   0.6103   4.915   4,6   .04217
  Year: Δ9-THC                                                 4.8429     1.4866    3.258    .0173                          
  (Year)\^3: Δ9-THC                                            2.7165     1.2130    2.239    .0664                          
  *Major_CVS\~poly(Year, n=4)\*Δ9-THC+CBDM+Tobacco+Opioids*                                                                 
  Δ9-THC                                                       0.5267     0.1820    2.894    .0178   0.4244   8.374   1,9   .01777
  *Majors2013\~poly(Year, n=4)\*Δ9-THC+CBDM+Tobacco+Opioids*                                                                
  (Year)\^3: Δ9-THC                                            4.7555     1.0784    4.410    .0070   0.7843   9.179   4,5   .01592
  Year: Δ9-THC                                                 3.3902     1.2164    2.787    .0386                          
  (Year)\^2: Δ9-THC                                            −3.6253    1.3525    −2.680   .0438                          

Abbreviation: df, degrees of freedom.

Discussion {#section8-0009922819861281}
==========

This study portrays a detailed picture of congenital defects in the state of Colorado based on the latest intrastate defect registry data from CRCSN and provides compelling evidence that the generally rising pattern both of individual defects and of systems levels summary and total measures closely parallels the rise in cannabis use in Colorado in the context of static or falling levels of other drug use.

While there is substantial heterogeneity in the trend of birth defects in Colorado, the overall trend of the CRCSN dataset is upward, a trend that closely parallels cannabis use during the progression of that state toward cannabis legalization. This is reflected in some of the most common birth defects such as ASD, PDA, VSD, and Down's syndrome and also in summary measures such as central nervous, cardiovascular, respiratory, chromosomal, and genitourinary defects, the overall total defects in both 2013 and 2014 and on principal component analysis. Indeed, ASD and PDA showed an uptick temporally associated with rising cannabis use. Cannabis use showed a statistically significant rise about 2007 related to the movement toward cannabis legalization. Moreover, the relationship to cannabis use was robust to multivariate adjustment with all other drug use. Data implicated several cannabinoids including Δ9-tetrahydrocannabinol, Δ8-tetrahydrocannabinol, tetrahydrocannabivarin, cannabinol, and cannabidiol. Although the relationship with cannabidiol is temporally complex, data show that the relative elevation of cannabis-related defects compared with non--cannabis-related defects peaked in 2009 to 2010 when cannabidiol exposure was peaking.

It should be underscored again that the reported changes are all at the associational level only: such a study cannot by itself establish or interrogate causal pathways.

Moreover, as has been described elsewhere, numerous published mechanistic reports link PCE with molecular pathways to teratogenesis and form a critical backdrop and highly pertinent context to the present report.^[@bibr18-0009922819861281][@bibr19-0009922819861281][@bibr20-0009922819861281][@bibr21-0009922819861281][@bibr22-0009922819861281]-[@bibr23-0009922819861281]^ This confluence of strong mechanistic links together with the present compelling teratological profile in the situation where the use of other drugs is uniformly static or falling strengthens the argument that causal pathways may be operating in clinical populations.

Space precludes detailed consideration of possible teratogenic mechanisms, but these have been addressed elsewhere.^[@bibr18-0009922819861281][@bibr19-0009922819861281][@bibr20-0009922819861281][@bibr21-0009922819861281][@bibr22-0009922819861281]-[@bibr23-0009922819861281]^ Neurotoxic mechanisms include withdrawal of glutamate receptors from synapses,^[@bibr24-0009922819861281]^ misconstruction of synapses from disruption of neurexin-neuroligin synaptic scaffolding,^[@bibr25-0009922819861281]^ excessive dendritic and spine pruning,^[@bibr26-0009922819861281]^ mitochondrial impairment,^[@bibr27-0009922819861281]^ stem cell inhibition,^[@bibr28-0009922819861281]^ CB1R-mediated neuraxis inflammation,^[@bibr29-0009922819861281]^ and cytoskeletal impairment and motility disruption.^[@bibr30-0009922819861281]^ Cardiovascular toxic mechanisms include inflammatory vasculitis and CB1R signaling to CB1R-rich endovascular and endocardial tissues.^[@bibr31-0009922819861281],[@bibr32-0009922819861281]^ Importantly, cannabis has been described as blocking both notch^[@bibr33-0009922819861281],[@bibr34-0009922819861281]^ and robo-slit receptor-ligand^[@bibr35-0009922819861281]^ signaling, which are important as both neuronal and vascular guidance cues,^[@bibr36-0009922819861281]^ and critically involved in heart and brain morphogenesis.^[@bibr36-0009922819861281]^ Cannabis induces severe epigenetic disruption^[@bibr22-0009922819861281],[@bibr37-0009922819861281][@bibr38-0009922819861281]-[@bibr39-0009922819861281]^ and has long been known to stimulate micronucleus formation and genetic anomalies secondary to chromosomal missegregation.^[@bibr22-0009922819861281],[@bibr40-0009922819861281]^

The present work did not have access to Coloradan early termination of pregnancy for anomaly data. Since many of the defects mentioned are known to be carefully sought by prenatal screening programs and have high applicable termination rates, the present results represent underestimates and set a lower bound for effect, which is likely to be greatly exacerbated by incorporation of the complete dataset.

Some discussion of the attribution of cannabis association to the listed defects is appropriate. Many of the defects listed as cannabis-associated have been attributed as such based on the large population survey of Forrester and Merz from Hawaii in 2007.^[@bibr15-0009922819861281]^ While this article is an outlier in the clinical cannabis-related teratogenesis literature, albeit highly concordant with previous animal studies,^[@bibr1-0009922819861281],[@bibr2-0009922819861281]^ its very uniqueness places it in a signal position to face the most stringent test of predictive theories, namely, the test of prediction of future trends. By this test, the Forrester-Merz article towers above the remainder of the literature. It alone predicts the increased incidence of ASD, Downs' syndrome, microcephaly, and chromosomal defects found in the present study. Moreover, this is the only study that explains the current pattern of cannabis-related defects such as ASD, Down's syndrome, VSD, encephalocele, limb reductions, anotia, and gastroschisis across the high cannabis-using states of the United States^[@bibr41-0009922819861281]^ and recently reported elevated rates of limb defects in France in hemp-fed cattle and babies.^[@bibr42-0009922819861281],[@bibr43-0009922819861281]^ As noted above, pyloric stenosis was omitted from the cannabis-related group as it has not been independently verified by other studies, and spina bifida is believed to share much in common with other neural tube closure defects such as anencephalus so this has been included.

Four of 4 longitudinal studies of cortical executive functioning following PCE indicate serious deficits in cerebral associational function.^[@bibr44-0009922819861281][@bibr45-0009922819861281][@bibr46-0009922819861281][@bibr47-0009922819861281]-[@bibr48-0009922819861281]^ Data on these deficits are not included within the CRCSN dataset, which therefore forms an additional disease burden to that described above. However, one notes that there has been a movement in Colorado for several years to declare a state of medical emergency related to a rapidly accelerating renaissance of autistic spectrum disorders in that community.^[@bibr49-0009922819861281]^ Importantly, rapid growth of autism in Colorado may shortly overshadow the classical anomalies described in the present report, which again suggests that this work describes a lower bound of cannabis teratogenesis.

Taken together, these various data imply that the full spectrum of cannabis-associated defects is potentially much broader than has previously been delineated. It may still be expanding.

A major finding of this statistical study was that models quartic in time outperformed strictly linear models. This suggests a feed-forward--type positive-feedback process.

In October 2018, the CRCSN revised their total database from 2000 to 2014 without explanation in a manner that mainly affected the total congenital anomalies. The previous historical totals from 2000 to 2013 appear as indicated.

This study has several strengths. Colorado is unusual among the United States in that it makes extracts from its birth defects register publicly available. Colorado is also unusual as it is one of the only states with legal cannabis to do so. This study also utilizes the very large nationally representative NSDUH dataset to assess intrastate drug exposure. Limitations include the lack of individual-level drug use data, which might be available to a case-control study. Due to the uncertainties involved with self-report studies,^[@bibr6-0009922819861281]^ we would suggest that future studies employ objective evidence of drug exposure such as hair analysis.^[@bibr50-0009922819861281]^

Conclusion {#section9-0009922819861281}
==========

An excess of 11 753 to 20 152 birth defects occurred in Colorado from 2000 to 2014, which represents a 6.7- to 9.4-fold excess of growth in defects compared with growth in births. Defects in 6 of 8 major organ systems increased significantly in frequency. While other drug use was falling over this period, cannabis use alone rose. Cannabis and many cannabinoids were shown to be associationally linked with this rise with correlation coefficients up to 0.78, were confirmed on bivariate analysis, and were robust to multivariate adjustment. In the context of multiple mechanistic pathways, causality is strongly implied. Longitudinal case-control series denominated by an objective measures of drug use are indicated.
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